The goal of this study is to evaluate if vasopressin can elevate systemic arterial blood pressures without having a significant effect on pulmonary arterial pressures. Because patients who have undergone Fontan procedures rely on low pressures across the pulmonary vascular bed to maintain cardiac output, vasoactive agents that concomitantly increase systemic and pulmonary pressures may have a deleterious effect in this specific patient population. Hypothesis: In patients with Fontan physiology, vasopressin will increase systemic BP by 20% above baseline, without increasing the transpulmonary gradient.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in systemic (aortic) blood pressure
Timeframe: Pre-dose, every 5 minutes post-dose for approximately 15 minutes (post-baseline values will be averaged)
Change in pulmonary artery pressure
Timeframe: Pre-dose, every 5 minutes post-dose for approximately 15 minutes (post-baseline values will be averaged)
Change in transpulmonary gradient
Timeframe: Pre-dose, every 5 minutes post-dose for approximately 15 minutes (post-baseline values will be averaged)
PVR/SVR Ratio
Timeframe: Pre-dose, every 5 minutes post-dose for approximately 15 minutes (post-baseline values will be averaged)